7Baggers
 Published on: 2025-11-16 22:10:23  newser.com Mon, 17 Nov 2025 04:10:23 GMT
 published on: 2025-11-15 00:27:20  newser.com Sat, 15 Nov 2025 06:27:20 GMT
 published on: 2025-11-14 18:28:12  newser.com Sat, 15 Nov 2025 00:28:12 GMT
 Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens  Investing.com Nigeria Fri, 14 Nov 2025 13:13:33 GMT
 published on: 2025-11-14 04:41:04  newser.com Fri, 14 Nov 2025 10:41:04 GMT
 published on: 2025-11-14 02:04:28  newser.com Fri, 14 Nov 2025 08:04:28 GMT
 prelude therapeutics reports q3 2025 financial results  MSN Fri, 14 Nov 2025 02:36:05 GMT
 Prelude Therapeutics (PRLD) Reports 117% Increase in Q3 Revenue  GuruFocus Wed, 12 Nov 2025 13:10:34 GMT
 Prelude Therapeutics reports Q3 EPS (26c) vs. (43c) last year  TipRanks Wed, 12 Nov 2025 13:08:47 GMT
 Prelude Therapeutics sees cash runway into 2027  TipRanks Wed, 12 Nov 2025 12:57:20 GMT
 Prelude Therapeutics Reports Q3 2025 Financial Results  TipRanks Wed, 12 Nov 2025 12:37:45 GMT
 Prelude Therapeutics Inc Q3 Loss Decreases, Beats Estimates  Nasdaq Wed, 12 Nov 2025 12:31:00 GMT
 prelude therapeutics inc sec 10-q report  TradingView Wed, 12 Nov 2025 12:23:00 GMT
 Prelude Therapeutics Q3 net loss narrows  MarketScreener Wed, 12 Nov 2025 12:16:28 GMT
 Published on: 2025-11-12 00:31:21  newser.com Wed, 12 Nov 2025 06:31:21 GMT
 published on: 2025-11-11 03:41:52  newser.com Tue, 11 Nov 2025 09:41:52 GMT
 published on: 2025-11-09 22:52:28  newser.com Mon, 10 Nov 2025 04:52:28 GMT
 published on: 2025-11-05 05:36:39  newser.com Wed, 05 Nov 2025 11:36:39 GMT
 prelude therapeutics cmo jane huang departs  MSN Wed, 05 Nov 2025 10:04:21 GMT
 prelude therapeutics shifts focus to jak2 and kat6a programs by investing.com  Investing.com Nigeria Wed, 05 Nov 2025 07:39:42 GMT
 published on: 2025-11-05 00:32:44  newser.com Wed, 05 Nov 2025 06:32:44 GMT
 Incyte (INCY) Secures $935M Deal with Prelude Therapeutics for J  GuruFocus Wed, 05 Nov 2025 02:00:13 GMT
 incyte (incy) secures exclusive option on jak2v617f program  GuruFocus Wed, 05 Nov 2025 01:30:00 GMT
 incyte (incy) secures $935m deal with prelude therapeutics for j  GuruFocus Tue, 04 Nov 2025 15:05:53 GMT
 major shift in prld stock: what’s behind the surge?​  StocksToTrade Tue, 04 Nov 2025 15:02:00 GMT
 incyte aboard, smarca2 shift by prelude enshrouds foghorn  BioWorld MedTech Tue, 04 Nov 2025 15:00:00 GMT
 incyte inks option agreement with prelude for jh2 inhibitor program  Seeking Alpha Tue, 04 Nov 2025 14:26:43 GMT
 prelude therapeutics signs option agreement with incyte  TipRanks Tue, 04 Nov 2025 14:22:15 GMT
 prelude therapeutics’ stock performance: rise or risk?  timothysykes.com Tue, 04 Nov 2025 14:19:00 GMT
 Prelude Therapeutics Announces Management Changes  TradingView Tue, 04 Nov 2025 13:55:00 GMT
 prelude therapeutics cmo jane huang departs  TipRanks Tue, 04 Nov 2025 13:29:21 GMT
 prld's financial outlook: cash runway extended to 2027  GuruFocus Tue, 04 Nov 2025 13:11:14 GMT
 incyte (incy) secures option for jak2v617f program in $910m deal  GuruFocus Tue, 04 Nov 2025 13:07:30 GMT
 incyte (incy) secures exclusive option on jak2v617f program  GuruFocus Tue, 04 Nov 2025 13:07:11 GMT
 prelude therapeutics sees cash runway into 2027  TipRanks Tue, 04 Nov 2025 12:41:18 GMT

Prelude Therapeutics Incorporated
(NASDAQ:PRLD) 

PRLD stock logo

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid...

Founded: 2016
Full Time Employees: 55
CEO: Krishna Vaddi  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends